Concepedia

Yonggui Hong

YH

3

Publications

108

Citations

3

H-Index

2022

Active since

Affiliations

First Affiliated Hospital of Henan University of Science and Technology(Current)

Anyang Tumor Hospital

Jiangsu Hengrui Medicine (China)

Nanyang Medical College

Zhengzhou University

Yonggui Hong is an author at First Affiliated Hospital of Henan University of Science and Technology specializing in cancer therapeutics, radiation oncology, and medicine.

Top concepts

Publications per year

2022–2024

3

Publications

3

Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial

Xiangrui Meng, Tao Wu, Yonggui Hong et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 82 citations

, , +6

A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma

Ning Li, Tao Wu, Yonggui Hong et al. · BMC Medicine · 2022 · 13 citations · Full text

Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study

Xiangrui Meng, Junsheng Wang, Jin Xia et al. · European Journal of Cancer · 2024 · 13 citations

Rows per page

1–3 of 3